Guangdong-Hong Kong-Macao Greater Bay Area International Research Platform
for Aptamer-based Translational Medicine and Drug Discovery (HKAP)
Supported by HK Government
Aptamer-functionalized Osteoblast-targeting Delivery System for Osteogenic siRNAs to Achieve Cell-specific RNA Interference for Bone Anabolic Therapy (2014.2.1-2015.1.31, HK$25,000)
ITF/14-15/05-SCMD
(ITC)
FRG/12-13/086
(HKBU-RC)
Understanding the molecular mechanism in failure of osteoblast-mediated repair for articular bone erosion during progressive rheumatoid arthritis: Role of casein kinase-2 interacting protein-1 in controlling osteoblast function (2014. 3.1-2016.8.31, HK$606,223)
Toward targeted therapy in advanced pancreatic cancer: A smart Triptolide - Nucleolin aptamer conjugate (2014-2016, HK$2,339,560)
Cell-specific Aptamer Facilitates Triptolide Selectively Targeting Fibroblast-like Synoviocytes and Specifically Reducing Exposure to Liver Cells (2014.3-2015.8, RMB 1,000,000)
Toward an emerging paradigm of network medicine: An innovative platform to combinational herbs / compounds-based drug discovery for complex diseases (2013. 9.1-2016.2.29, HK$3,000,000)
Screening on anti-rheumatic herbal medicines (2013. 1.1-, HK$1,000,000)
Prof. Ge Zhang
Aptamer-functionalized osteoblast-targeting delivery system for osteogenic siRNAs to achieve cell-specific RNA interference for bone anabolic therapy (2015.1.1-2017.12.31, HK$1,035,000)
Role of osteoclast-derived exosomal miR-214 in regulating osteoblastic bone formation (2017.1.1-2019.12.31, HK$1334,644)
The role of osteoclastic miR-214-3p in early osteoarthritis development (2018.1.1-2020.6.30, HK$871,855)
Targeting sclerostin to reverse established osteoporosis: Aptamer characterization and evaluation for drug discovery (2017.01.01-2018.12.31, HK$1000,000)
Toward a novel bone anabolic strategy for aged postmenopausal osteoporosis: Inhibiting miR-214 in osteogenic cells for promoting bone formation (2015.9.1-2017.8.31, HK$144,000.00)
The Role of Osteoclastic MiR-214-3p in Early Osteoarthritis Development (2018.01.01-2019.12.31, HK$127,500.00)
Role of miR-214 from osteoclast in regulating osteoblastic bone formation (2014.8.1-2017.7.31, HK$ 2,981,576)
Functional role of Plekho1 within osteoblast in regulating BMP signaling and bone formation during age-related osteoporosis development in both genders: from molecular mechanism to translational therapeutics (2016.1.1- 2017.12.31, HK$1,993,740)
Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipid nanoparticles for therapeutic genome editing of miR-214 in osteosarcoma (2018.3.1-2020.2.28, HK$2,993,400)
Therapeutic RNAi targeting CKIP-1 to reverse severe postmenopausal osteoporosis (2012.1.1-2014.6.31, HK$920,000)
Toward a novel bone anabolic strategy for aged postmenopausal osteoporosis: Inhibiting miR-214 in osteogenic cells for promoting bone formation (2013. 1.1-2015.12.31, HK$950,000)
Skeletal role of CK2-interating Protein-1 in Regulating Osteoblastic Bone Formation: Molecular Mechanism and Reversing Osteoporosis (2013.1.1-2016.12.31, HK$753,925)
Aptamer-functionalized Osteoblast-targeting Delivery System for Osteogenic siRNAs to Achieve Cell-specific RNA Interference for Bone Anabolic Therapy (2013.7.1-2015.6.31, HK$135,000)
HKBU 261113
(GRF/RGC)
RC-IRMS/12-13/02-SCMD
(HKBU-RC)
HKBU Patent Grant
(HKBU-RC)
HKBU 12102914
(GRF, RGC)
HKBU12114416
(GRF, RGC)
HKBU12101117
(GRF, RGC)
UIM/298
(ITF)
RC-IRMS/13-14/02CMTR
(HKBU-RC)
FRG2/14-15/010
(HKBU-RC)
FRG2/16-17/011
(HKBU-RC)
HKBU 479111
(GRF, RGC)
RC-ICRS/14-15/01
(HKBU-RC)
RC-IRMS/15-16/01
(HKBU-RC)
HKBU 478312
(GRF, RGC)
N_HKBU435/12
(NSFC-RGC)
FRG2/12-13/027
(RC-HKBU)
FRG1/13-14/024
(RC-HKBU)
ID (Funding Body)
PI
Title (Start-End, Project Fund)
Prof. Aiping Lyu
HKBU 12122516
(GRF/RGC)
Does aberrantly overexpressed CKIP-1 suppress osteoblast-mediated articular bone repair in inflammatory arthritis? A collagen-induced non-human primate arthritis model (2017.1.1-2019.6.30, HK$795,400)
Toward cell-targeted therapeutics in osteosarcoma: A smart Triptolide-aptamer conjugate (2015-2018, HK$1,000,000)
Characterization of linkage between symbiotic gut microbes and fatty acid metabolism in rheumatoid arthritis patients (2014-2019.2.28, HK$2,944,160)
The next generation aptamer screening system: a SMART, high yield, label-free and high throughput microfluidic platform (2018.04.01-2020.03.31)
Targeting a Critical Disease Biomarker - C Reactive Protein: A Combination Therapy Using Leflunomide and Ligustrazine in Rheumatoid Arthritis (2015-2017, HK$2,833,595)
A Unique Platform for Drug Discovery of Combinational Drugs & Chinese Herbal Medicine / Compounds (2014-2017, HK$3,000,000)
Construction of Integrated Bioinformedicine & Translational Science Research (2015.8.15-2018.8.14, HK$6,297,218)
Strategic Development of Aptamer-based Drug Discovery Platform (2018.1.1-2019,12.31 HK$5,000,000)
Toward precision medicine in aged osteoporotic subgroup with poor BMP responsiveness: Oligopeptide-chalcone derivative conjugate targeting osteoblasts for Smurf1 inhibition and bone formation enhancement (2018.01-2020.12, HK$1,998,900)
Gnt#CAS14BU/CAS14201
(CAS Croucher)
RC-IRMS/1314/3A-SCM
(HKBU-RC)
RC-IRMS/16-17/03
(HKBU-RC)
RC-ICRS/16-17/01
(HKBU-RC)
SDF16-0603-P02
(HKBU-RC)
SDF15-0324-P02(b)
(HKBU-RC)
SDF13-1209-P01
(HKBU-RC)
RC-IRMS/14-15/02
(HKBU-RC)
FRG2/13-14/006
(RC-HKBU)
Role of MiR-214 within Osteoclast in Regulating Osteoblastic Bone Formation (2014.9.1-2016.8.31, HK$135,000)
HKRGC Early Career Scheme (ECS) 22200515
HKBU TDG 2017-18-04
HKBU SKL-CRF, SKLP_1718_P01
Hong Kong Baptist University Faculty Research Grant Category II, 2016-2017 [FRG2/16-17/047]
Hong Kong Baptist University Faculty Research Grant Category II [FRG2/14-15/072]
NSFC Young Scientists Project, 21505110
Hong Kong Baptist University Faculty Research Grant Category II, [FRG2/16-17/062]
NSFC General Program, 51773173
Dr. Kangning Ren
Microfluidic Platform for Rapid, Low-cost, High-Throughput, Automated Test of Antimicrobial Susceptibility, 2016-18, HK$641,200
A Centrifugal Microfluidic Device for Rapid Antimicrobial Drug Efficacy Testing in Resource-Limited Environment, 2016-18, RMB210,000 (direct fund)
Drug Efficacy Testing Platform for Personalized Treatment of Bacterial Infection Based on 2D Gradient Array, $139,308
Novel Polymeric Microfabrication Strategy for Generating Multifunctional Self-Cleaning Coating, 2018-2021, RMB610,000 (direct fund)
Strategy for Promoting Student-orientated, Interactive Teaching/Learning of Major Election Courses, 2018-2019, HK$195,000
Development of a microfabricated lung mimic device to study the toxicity of air pollutants, HK$600,000.00
Practical Method for Creating Superhydrophobic Coating for Real Applications, HK$142,196.00
Rapid, Low-cost, High-Throughput, Automated Test of Antimicrobial Susceptibility, 2015/16, 2015-2017, HK$120,000